simvastatin / Generic mfg. - LARVOL DELTA

Real-world impact of lipophilic statins on survival outcomes in polycythemia vera and essential thrombocythemia (ASH 2025) - "Preclinical studies have suggested that lipophilic statins—such as simvastatin, lovastatin, and atorvastatin—may disrupt membrane lipid rafts, thereby interfering with JAK2-V617F–mediated signaling... In this large, real-world cohort study, lipophilic statin use was associated with a significant reduction in all-cause mortality among patients with polycythemia vera or essential thrombocythemia. These findings highlight the potential role of statins as adjunctive therapy in myeloproliferative neoplasms and warrant further prospective evaluation."

Clinical • Real-world • Real-world evidence • Acute Myelogenous Leukemia • Chronic Eosinophilic Leukemia • Essential Thrombocythemia • Hematological Disorders • Hematological Malignancies • Leukemia • Myeloproliferative Neoplasm • Polycythemia Vera • Thrombocytosis

Simvastatin targets the cholesterol–bile acid axis to improve ALL survival by remodeling the metabolic microenvironment (ASH 2025) - "Geneset enrichment analysis (GSEA) further indicated that liver-infiltrating leukemic cells in the simvastatincombined treatment group were significantly enriched for pathways related to metabolicreprogramming, immune modulation, and signal transduction. These features were not observed in theirbone marrow-resident counterparts.Collectively, our findings suggest T-CA as a clinically promising biomarker and demonstrate thatsimvastatin's synergistic efficacy is mediated through metabolic-immune niche reprogramming, providinga rational basis for microenvironment-targeted therapies."

Acute Lymphocytic Leukemia • Hematological Malignancies • Immune Modulation • Immunology • Leukemia • Metabolic Disorders • T Acute Lymphoblastic Leukemia • ABCB1 • CD4 • HNRNPUL1 • IL2RA • MEF2D

BH22 Alopecia areata caused by an adverse reaction to denosumab. (PubMed, Br J Dermatol) - "Alopecia areata and other autoimmune reactions have been seen with other biologic drugs, including dupilumab (interleukin-14 and interleukin-3 inhibitor) and anti-tumour necrosis factor (TNF)-α medications. Based on the timeline, it was unlikely that simvastatin had triggered the process. This case is one of only a handful of reports of denosumab inducing alopecia areata and it is important to consider this as a cause in patients taking this medication."

Journal • Alopecia • Dermatology • Dyslipidemia • Immunology • Musculoskeletal Diseases • Oncology • Orthopedics • Osteoporosis • Rheumatology

Dissecting the difference between positive and negative brain health sentiment using X data. (PubMed, Front Digit Health) - "These X-posts also mention coping strategies like using medications such as lorazepam and simvastatin, or consuming comfort foods like pizza. In contrast, positive sentiments emphasize resilience and improvement, with mentions of mindfulness, supplements, and medications like doxycycline and pregabalin. The study also highlights the risk of disseminating information about dietary and drug supplements that may not be suitable for public use due to serious side effects, such as Chaga mushrooms, which, despite being associated with positive sentiment, are known to cause renal failure in certain cases. Overall, the study profiles the use of positive and negative brain health sentiment of X, which underscores both the advantages and risks of using X (formerly Twitter) as a platform for sharing brain health-related information."

Journal • CNS Disorders • Cognitive Disorders • Infectious Disease • Inflammation • Mood Disorders • Novel Coronavirus Disease • Psychiatry • Renal Disease

L-arginine-induced chronic pancreatitis in mice: Evaluating effects of pirfenidone and simvastatin. (PubMed, World J Gastrointest Pharmacol Ther) - "Combination of pirfenidone and simvastatin demonstrated a synergistic therapeutic effect in reducing inflammation, fibrosis, and oxidative stress in an L-arginine-induced chronic pancreatitis mouse model, suggesting promise for chronic pancreatitis management."

Journal • Preclinical • Fibrosis • Immunology • Oncology • Pancreatitis • GPX1 • IL10 • TGFB1 • TNFA

Association of impaired medication adherence with subsequent clinical recognition of dementia or cognitive impairment in older veterans. (PubMed, Eur Geriatr Med) - "Among veterans without clinically recognized DCI, lower baseline medication adherence was associated with an increased risk for future clinically recognized DCI. Further studies should seek to disentangle whether low adherence is a risk factor for future DCI or an indicator of existing but not yet recognized DCI and whether this can inform clinical practice decisions."

Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia

Network pharmacology combined with experiments to explore the molecular mechanism of Jiawei Erzhi pill protects against atherosclerosis by inhibiting ferroptosis. (PubMed, J Tradit Chin Med) - "JWEZP improved AS by inhibiting ferroptosis. The study provides a scientific basis for further research and validation of JWEZP as a potential therapeutic for AS."

Journal • Atherosclerosis • Cardiovascular • APOE • GPX4

CER-4-T2D: Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study (clinicaltrials.gov) - P=N/A | N=781430 | Active, not recruiting | Sponsor: Brigham and Women's Hospital | Trial completion date: Jul 2024 ➔ Jul 2026 | Trial primary completion date: Jul 2024 ➔ Jan 2026

HEOR • Trial completion date • Trial primary completion date • Cardiovascular • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Sex-specific mitigation of oxidative and inflammatory cardiac alterations by folic acid and simvastatin in chronic mild hyperhomocysteinemia. (PubMed, Biochem Pharmacol) - "In females, HHcy decreased GPx and nitrites and increased IL-6 and RELA; FA and SIM normalized these, with SIM strongly activating SOD, CAT, GPx, and cytosolic NRF2 even in controls. These findings demonstrate that FA and SIM provide acute cardioprotection under chronic HHcy by restoring redox balance and attenuating inflammatory signaling in a sex-dependent manner, highlighting SIM's pleiotropic enhancement of NRF2-mediated antioxidant defenses and nitric oxide bioavailability."

Journal • Cardiovascular • Inflammation • Metabolic Disorders • IL10 • IL1B • IL6 • NFE2L2 • RELA

Renal Toxicity of Rosuvastatin: A Case Report. (PubMed, Cureus) - "He had initially been treated with simvastatin, though it was changed to rosuvastatin for stronger effects on cholesterol and cardiovascular risk reduction. He had severe esophageal disease, which was at risk of a flare with coming off the pantoprazole, so we elected to stop rosuvastatin first. After stopping rosuvastatin, the kidney function returned to baseline, and the abnormal urine testing resolved."

Journal • Acute Kidney Injury • Cardiovascular • Coronary Artery Disease • Dyslipidemia • Gastrointestinal Disorder • Hypertension • Nephrology • Renal Disease

Utilizing Physiologically Based Pharmacokinetic Modeling and Virtual Simulation for Simvastatin Tablets to Evaluate the Sensitivity of Using Parent vs Metabolite as Analyte on Bioequivalence Assessment. (PubMed, AAPS J) - "The VBE simulation results further implied that in some cases, SVA as analyte is more sensitive to show drug exposure differences and may enhance the assessment of formulation effect, as compared to SV. This aligns with current PSG recommendations."

Journal • PK/PD data

LSTR: Triple Antibiotic Paste vs Simvastatin for Lesion Sterilization and Tissue Repair in Primary Molars. (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Dow University of Health Sciences

New P2 trial

Discovery of hemostatic component combination from Nelumbinis Receptaculum using dual machine learning spectrum-effect analysis. (PubMed, J Ethnopharmacol) - "Using DML-SER, a potential HCC containing six compounds were discovered and initially verified, which could provide a material basis to facilitate mechanism studies, quality control and clinical application of NR."

Journal • Gastroenterology • Gastrointestinal Disorder

Fusion of Tumor Cells with Lipid-Associated Macrophages Drives Metastatic Progression of Breast Cancer. (PubMed, Cancer Res) - "Fusion cells accumulated abundant intracellular lipid droplets and were highly sensitive to simvastatin treatment in vitro and in vivo. Together, this study uncovered that CBX3-SNX10-ANO6 signaling facilitates generation of an aggressive tumor-LAM fusion cell subpopulation that promotes metastasis, revealing an alternative metastatic mechanism and exposing putative therapeutic vulnerabilities. Single-cell transcriptomic profiling combined with functional and clinical validation identifies fusion of tumor cells and lipid-associated macrophages mediated by the CBX3-SNX10-ANO6 axis as a potentially targetable mechanism driving cancer metastasis."

Journal • Breast Cancer • Oncology • Solid Tumor • ANO6 • CBX3 • CD68 • CTCs • EPCAM

Prognostic model for osteosarcoma: RNA diagnostics, tumor microenvironment and immunotherapy response. (PubMed, J Orthop) - "The drug sensitivity prediction of patients showed high consistency in the two models, and in vitro experiments proved that osteosarcoma cells were sensitive to simvastatin...The drug sensitivity prediction of patients showed high consistency in the two models. Overall, our study provides reliable prognostic and immune-related biomarkers for osteosarcoma patients, and valuable insights for therapeutic strategy and therapy toxicity."

Biomarker • IO biomarker • Journal • Oncology • Osteosarcoma • Sarcoma • Solid Tumor • TPD52

Cross-Sectional and Longitudinal Analyses of the Association Between Statin Use and Age-Related Hearing Loss. (PubMed, Drugs Aging) - "Overall, the findings suggest statin benefits for mid-to-high frequency hearing for middle-aged to older adults at early stages of ARHL. On the basis of evidence suggesting that some statins have beneficial effects on hearing, well-controlled clinical trials are needed to examine effects of statin use and statin types on ARHL in the general population."

Clinical • Journal • Otorhinolaryngology

Do the pharmacokinetics of statins explain psychiatric symptom improvement from adjunctive statin prescribing in severe mental illness? Three target trial emulation studies. (PubMed, BMJ Ment Health) - "There is currently not enough evidence to guide the prescription of statins for psychiatric symptom improvement in patients with SMI. If there is an effect of statins, it may be through specific statin-antipsychotic combinations."

Journal • PK/PD data • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry • Schizophrenia

Combination of ALK2 and cholesterol targeting agents exploits linked genetic and metabolic dependencies in diffuse midline glioma (SNO 2025) - "Drug-combination screens identified clinically well-tolerated statins, including simvastatin/lovastatin which target the rate-limiting cholesterol synthesis enzyme HMG-CoA reductase, and estrogen receptor inhibitors, including Tamoxifen, which exhibits off-target effects on EBP, as sensitisers to ALK2i...Forced differentiation of DMG cells to an astrocyte-like cell state increased cholesterol production and led to a significant decrease in M4K2009 sensitivity and synergy with statins, which was phenocopied when DMG cells were co-cultured with normal astrocytes. This was overcome in vitro, ex vivo and in vivo using a triple combination including a LXR agonist (LXR623) to promote cholesterol export. We identify a previously unappreciated link between ALK2 signalling and cholesterol homeostasis which may be exploited clinically by combining ALK2i with routinely-used statins and BBB-penetrant LXR agonists."

Brain Cancer • Diffuse Midline Glioma • Glioma • Solid Tumor • ABCA1 • ACVR1 • SREBF2

Antimicrobial and Anti-inflammatory Effects of Simvastatin as an Intracanal Medication (clinicaltrials.gov) - P=N/A | N=54 | Recruiting | Sponsor: Hadeer Maher Mostafa Mohamed

New trial

Severe Rhabdomyolysis in an Elderly Patient With Diabetes and Vascular Disease: Interplay of Statin Therapy, Sodium-Glucose Cotransporter-2 (SGLT2) Inhibition, and Thiazide-Induced Hypokalemia. (PubMed, Cureus) - "We report a 78-year-old woman with diabetes, hypertension, hyperlipidemia, and carotid artery disease, hypothyroidism, who developed severe rhabdomyolysis, acute kidney injury, and transaminitis while taking simvastatin, hydrochlorothiazide, and empagliflozin. This case underscores the multifactorial etiology of rhabdomyolysis in elderly vascular patients, where dehydration and hypokalemia from thiazides and SGLT2 inhibitors may synergize with statin-induced myotoxicity, complicating evaluation when troponin is elevated without ischemic changes. Clinicians should maintain a high index of suspicion for rhabdomyolysis in patients with new muscle pain, weakness, or fatigue after starting empagliflozin, especially when combined with statins and diuretics, and prioritize early recognition, medication review, and hydration to prevent serious complications."

Journal • Acute Kidney Injury • Cardiovascular • Diabetes • Dyslipidemia • Endocrine Disorders • Fatigue • Hypertension • Metabolic Disorders • Musculoskeletal Pain • Nephrology • Pain • Pulmonary Disease • Renal Disease

Grenz Ray Therapy for Porokeratosis Ptychotropica: A Case Report. (PubMed, Case Rep Dermatol) - "She was previously unsuccessfully treated with topical, intralesional and oral corticosteroids, topical vitamin D analogues, topical simvastatin-cholesterol cream, topical fluorouracil cream, acitretin, and CO2 laser assisted photodynamic therapy. This is the first reported case of PP being treated with Grenz rays. With no effective treatment, Grenz therapy may present a potential effective treatment for some patients."

Journal

CDT1 induces the formation of polyploid giant cancer cells and promotes centrosome amplification through the PLK4/SASS6 axis. (PubMed, Cancer Lett) - "Moreover, we identified simvastatin as a potent inhibitor of CDT1, effectively inhibiting CDT1-mediated centrosome amplification and PGCC formation. In summary, our findings reveal a critical role for CDT1 in driving centrosome amplification and PGCC formation through activation of the PLK4/SASS6 axis, which subsequently contributes to therapeutic resistance and malignant progression."

Journal • Oncology • CDT1 • PLK4

Long-term disease control of disseminated superficial actinic porokeratosis (DSAP) with simvastatin 2%/ cholesterol 2% cream. (PubMed, J Dtsch Dermatol Ges) - "SC cream is a promising long-term, targeted treatment for DSAP, offering sustained efficacy, good tolerability, and improved QoL. The individual tapering from daily use to a proactive approach twice a week may be a key factor for disease control and may become an important component of skin tumor prevention in this specific patient population."

Journal • Dermatology • Genetic Disorders • Oncology • Skin Cancer

Nanocarrier-Enhanced Simvastatin Modulates AMPK-ULK1 Pathway and Oxidative Stress in Alzheimer's Disease Model. (PubMed, Eur J Pharmacol) - "In conclusion, Simva exhibits notable neuroprotective effects in the AD rat model via antioxidative, anti-inflammatory, and autophagic pathways. Nanocarrier delivery further improves Simva's pharmacological effects, offering a promising AD therapeutic strategy."

Journal • Alzheimer's Disease • CNS Disorders • Inflammation • Pain • ACHE • IL1B • TNFA

Retraction Note: Simvastatin and Atorvastatin inhibit DNA replication licensing factor MCM7 and effectively suppress RB-deficient tumors growth. (PubMed, Cell Death Dis) - No abstract available

Journal • Oncology • MCM7